Immunoforge Co., Ltd.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
2
Ending by 2030
Aug 2030
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
No maintenance fee falls due on this company's record before Nov 14, 2027.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,700,598 | Modified Vasoactive Intestinal Peptides In force · High confidence | In force | High confidence | |
| US 10,940,182 | Use of Modified Vasoactive Intestinal Peptides in the Treatment of Hypertension In force · High confidence | In force | High confidence | |
| US 9,029,505 | Modified Vasoactive Intestinal Peptides In force · High confidence | In force | High confidence | |
| US 9,561,262 | Use of Modified Vasoactive Intestinal Peptides in the Treatment of Hypertension In force · High confidence | In force | High confidence | |
| US 9,919,032 | A Method for Administering a Sustained Release Formulation In force · High confidence | In force | High confidence | |
| US 11,052,132 | Methods and Compositions for Treating Cystic Fibrosis In force · High confidence | In force | High confidence | |
| US 10,722,590 | Elp Fusion Proteins for Controlled and Sustained Release In force · High confidence | In force | High confidence | |
| US 10,688,156 | Methods and Compositions for Treating Muscle Disease and Disorders In force · High confidence | In force | High confidence | |
| US 11,266,719 | Methods and Compositions for Treating Muscle Disease and Disorders In force · High confidence | In force | High confidence | |
| US 10,993,993 | Pharmaceutical composition for treating muscle atrophy or sarcopenia including glucagon-like peptide (GLP-1) or GLP-1 receptor agonist In force · From the USPTO record | In force | From the USPTO record |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
4 pending · 2 abandoned · 2 no status recorded